- CIIX’s multi-prong approach offers opportunity for investors
- Company to launch hemp-infused skin care product line in China
- Brick-and-mortar store planned for California, CBD biotech incorporated in Canada
- Online CBD store serves global Chinese-speaking population; Yelp style app helps Chinese-speakers find U.S. medical marijuana dispensaries
ChineseInvestors.com, Inc. (OTCQB: CIIX) is offering a unique opportunity for investors as the company pursues a multi-pronged approach to conquering the rapidly expanding global markets in cannabidiol products and the medical marijuana space in Canada. The company aims to be the world’s leading publicly traded Chinese nutritional company.
Globally, ChineseInvestors.com targets the global Chinese-speaking population with an online CBD store offering hemp-based products. Cannabidiol, or CBD, is a non-psychoactive cannabinoid that research is showing has numerous health benefits including the treatment of epilepsy. Many other CBD health benefits are being discovered, and the market is rapidly expanding.
The company announced earlier this week (http://nnw.fm/6EvTN) that its subsidiary, CBD Biotechnology Co. Ltd., has officially filed a record of its first line of non-industrial hemp-infused skin care products with the China Food and Drug Administration (CFDA). The product line is expected to launch in late August or early September and will position CBD Biotechnology as a first-mover in China’s CBD-based skin care market.
Another part of the company’s strategic plan to penetrate the Chinese-speaking market is the launch of a ‘Yelp’ style mobile app to help users locate dispensaries and discuss cannabis products in the U.S., along with a CBD retail store in the predominantly Chinese community of San Gabriel, California, where the company’s headquarters are located.
Other exciting developments from ChineseInvestors.com include the announcement of a bitcoin payment solution for its wholly-owned subsidiary, ChineseHempOil.com, Inc., and the company’s effort to become the first company in China to employ CBD oil as a treatment to relieve suffering for epilepsy and Alzheimer’s patients. The company plans to continue studying CBD oil’s efficacy as a treatment for these diseases and invest in CBD drug R&D enterprises, with an end goal of developing a variety of CBD drugs to treat epilepsy and Alzheimer’s.
Marijuana use is illegal in China, but cannabis-based oils, including hemp-based CBD, are legal, giving CIIX access to a market of almost two billion potential customers.
For more information, visit the company’s website at www.ChineseInvestors.com
More from NetworkNewsWire
Biotech Players Lead the Growth Charge in the Legal Cannabis Market
Algae Dynamics Corp.’s (ADYNF) Therapeutic Fortified Formulas Likely to Boost Endocannabinoid System
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
